From Analysis:
Causal Sequence of TDP-43 Nuclear Clearance to Cytoplasmic Aggregation in ALS Motor Neurons
What is the precise causal sequence of molecular events linking TDP-43 nuclear clearance to cytoplasmic aggregation in ALS spinal motor neurons — does loss of nuclear TDP-43 function (splicing dysregulation) precede or follow toxic cytoplasmic gain-of-function, and can time-resolved single-cell proteomics in iPSC motor neurons resolve this question?
The question is likely underpowered or misleading unless analyses preserve the key strata: TDP-43, ALS. Averaging across these strata could convert a causal subpopulation effect into a weak association.
No AI visual card yet
Curated pathway diagram from expert analysis
flowchart TD
A["Single-Nucleus Multiome
Chromatin Accessibility + Transcriptome"]
B["Cell-State Stratification
TDP-43 Loss States Across Neuron Types"]
C["Causal Sequence Analysis
TDP-43 Clearance Timing Resolution"]
D["Cryptic Exon Splicing Events
STMN2, UNC13A Mis-splicing Detection"]
E["Neuronal Subtype Vulnerability
Differential Sensitivity to TDP-43 Loss"]
F["Therapeutic Window Identification
Early Intervention Before Irreversible Loss"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#4a148c,stroke:#ce93d8,color:#ce93d8
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Theorist position for analysis 0ed3c364-07fd-4620-8e90-8bd33c14e370: Causal Sequence of TDP-43 Nuclear Clearance to Cytoplasmic Aggregation in ALS Motor Neurons
Source basis: Molecular Mechanisms of Phase Separation and Amyloidosis of ALS/FTD-linked FUS and TDP-43 (Aging and Disease, 2024, DOI 10.14336/ad.2023.1118). The stored gap context says: Mechanistic review of FUS/TDP-43 phase separation highlighted that the temporal ordering of nuclear loss-of-function versus cytoplasmic gain-of-function remains unresolved and therapeutically critical.
Primary hypothesis: RNA-binding protein condensa
Skeptic critique for analysis 0ed3c364-07fd-4620-8e90-8bd33c14e370: Causal Sequence of TDP-43 Nuclear Clearance to Cytoplasmic Aggregation in ALS Motor Neurons
The source paper motivates the gap, but motivation is not causal evidence. The main threat is that the observed association in Molecular Mechanisms of Phase Separation and Amyloidosis of ALS/FTD-linked FUS and TDP-43 could be downstream of disease stage, tissue composition, survival bias, or batch structure. The specific concern here is: in-vitro condensate rules may not transfer cleanly to crowded, stressed patient neurons.
The debat
Domain expert assessment for analysis 0ed3c364-07fd-4620-8e90-8bd33c14e370: Causal Sequence of TDP-43 Nuclear Clearance to Cytoplasmic Aggregation in ALS Motor Neurons
The practical path is feasible but should be staged. Stage 1 should reanalyze or collect human data at the needed resolution, preserving pathology, sex/genotype, region, and disease-stage covariates when relevant. Stage 2 should test RNA-binding protein condensate maturation from reversible phase separation to amyloid-like aggregation in a model where the proximal readout can be measured before overt toxicity. Stage 3 should co
{
"ranked_hypotheses": [
{
"title": "RNA-binding protein condensate maturation from reversible phase separation to amyloid-like aggregation as proximal driver in Causal Sequence of TDP-43 Nuclear Clearance to Cytoplasmic Aggregation in ALS Motor Neurons",
"description": "RNA-binding protein condensate maturation from reversible phase separation to amyloid-like aggregation should produce a measurable proximal phenotype before late disease pathology. The decisive test is time-resolved iPSC motor-neuron perturbations combining RNA stoichiometry, PTM mapping, live-cell condensate
No price history recorded yet
No clinical trials data available
No linked papers yet
Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.
No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.
Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.
High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.
Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.
Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
No DepMap CRISPR Chronos data found for ALS.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No governance decisions recorded for this hypothesis.
Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.
No knowledge graph edges recorded
neurodegeneration | 2026-04-27 | open
No comments yet. Be the first to comment!